Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative breast Cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar H, Vishal Gupta N, Jain R, Madhunapantula SV, Saravana Babu C, Kesharwani SS, Dey S, Jain V. A Review of Biological Targets and Therapeutic Approaches in the Management of Triple-Negative Breast Cancer.J Adv Res2023.

Sharma P. Biology and Management of Patients with Triple-Negative breast Cancer. Oncologist. 2016;21(9):1050–62.

Article  PubMed  PubMed Central  Google Scholar 

Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12(17):5018–22.

Article  CAS  PubMed  Google Scholar 

Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009;20(10):1639–46.

Article  CAS  PubMed  Google Scholar 

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

Article  CAS  PubMed  Google Scholar 

Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239–47.

Article  CAS  PubMed  Google Scholar 

Ferrero JM, Hardy-Bessard AC, Capitain O, Lortholary A, Salles B, Follana P, Herve R, Deblock M, Dauba J, Atlassi M, et al. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: results from the GINECO A-TaXel phase 2 study. Cancer. 2016;122(20):3119–26.

Article  CAS  PubMed  Google Scholar 

Tian S, Quan H, Xie C, Guo H, Lu F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–80.

Article  CAS  PubMed  Google Scholar 

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135(8):1961–9.

Article  CAS  PubMed  Google Scholar 

Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, Su S, Wang Q, Jin L, Wang Y et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.J Immunother Cancer2020, 8(1).

Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, Liu Q, Su S, Zeng Y, Jia W, et al. Multicenter phase II trial of Camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13(1):3011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514–21.

Article  CAS  PubMed  Google Scholar 

Yuan P, Xu BH, Wang JY, Ma F, Fan Y, Li Q, Zhang P. Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy. Chin Med J (Engl). 2012;125(5):775–9.

CAS  PubMed  Google Scholar 

Hu N, Zhu A, Si Y, Yue J, Wang X, Wang J, Ma F, Xu B, Yuan P. A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast Cancer. Front Oncol. 2020;10:565384.

Article  PubMed  Google Scholar 

Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, Zheng M, Zhang YN, Feng YL, Liu Q, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239–46.

Article  CAS  PubMed  Google Scholar 

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur J Cancer. 2019;112:57–65.

Article  CAS  PubMed  Google Scholar 

Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23.

Article  CAS  PubMed  Google Scholar 

Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. Cancer Biol Ther. 2015;16(2):225–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laessig D, Stemmler HJ, Vehling-Kaiser U, Fasching PA, Melchert F, Kolbl H, Stauch M, Maubach P, Scharl A, Morack G, et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology. 2007;73(5–6):407–14.

Article  CAS  PubMed  Google Scholar 

Zhang M, Liu J, Liu G, Xing Z, Jia Z, Li J, Wang W, Wang J, Qin L, Wang X, et al. Anti-vascular endothelial growth factor therapy in breast cancer: molecular pathway, potential targets, and current treatment strategies. Cancer Lett. 2021;520:422–33.

Article  CAS  PubMed  Google Scholar 

Miles DW, Dieras V, Cortes J, Duenne AA, Yi J, O’Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013;24(11):2773–80.

Article  CAS  PubMed  Google Scholar 

Bodzioch M, Bajger P, Forys U. Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling. J Cancer Res Clin Oncol. 2021;147(8):2281–99.

Article  PubMed  PubMed Central  Google Scholar 

Gourley C. Apatinib and etoposide: surprising efficacy of an oral combination. Lancet Oncol. 2018;19(9):1146–7.

Article  PubMed  Google Scholar 

Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gomez P, Van Eyll B, Bermejo B, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 2012;30(13):1484–91.

Article  CAS  PubMed  Google Scholar 

Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013;22(5):650–6.

Article  PubMed  Google Scholar 

Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30(9):921–9.

Article  CAS  PubMed  Google Scholar